Healio
SearchLoading
Healio
SearchLoading
Retinal image

Take Homes in Age-related Macular Degeneration
ByEsther M. Bowie, MD
ByCory Perla
Fact checked byChristine Klimanskis, ELS

Read more

January 11, 2024
1 min watch
Save

VIDEO: Faricimab demonstrates reduction in pigment epithelial detachment

ByEsther M. Bowie, MD
ByCory Perla
Fact checked byChristine Klimanskis, ELS

Healio
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions and subtitles off, selected

      In this video, Esther M. Bowie, MD, discusses a post hoc analysis comparing faricimab and aflibercept for the reduction of pigment epithelial detachment in patients with wet age-related macular degeneration.

      The data from the TENAYA and LUCERNE trials were presented at the American Academy of Ophthalmology meeting.

      “Faricimab seems to be good at decreasing pigment epithelial detachment, especially the ones with serous PED,” Bowie, professor of ophthalmology at Penn State Health Milton S. Hershey Medical Center, said.

      Reference:

      • Lim JI, et al. How effective is anti-Ang-2 and anti-VEGF (faricimab) for neovascular AMD with pigment epithelial detachments? Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
      Sources/Disclosures

      Collapse
      Source:

      Healio Interviews

      Disclosures: Bowie reports no relevant financial disclosures.

      Read more from Take Homes in Age-related Macular Degeneration

      View all

      Read more about

      wet age-related macular degeneration
      faricimab
      aflibercept
       

      Related Content